Developer docs
API playgroundTry for free, no card

Search company profiles

Cerberus Therapeutics

Full company profile

uuid000761g

Namestring
Cerberus Therapeutics
Legal namestring
Cerberus Therapeutics, Inc.
Websiteurl
cerberustx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Cerberus Therapeutics is a preclinical biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops VHH (variable heavy domain of heavy-chain-only antibody), or nanobody, platforms organized around two distinct programs: a Tolerance Induction platform for autoimmune diseases and a KappaLink platform for infectious diseases. Its technology is based on single-domain antibodies derived from camelid heavy-chain-only antibodies and is positioned for therapeutic applications in immunology and infectious disease indications.

The company was co-founded by Novalia Pishesha, who serves as CEO, alongside scientific co-founders Hidde Ploegh and Harvey Lodish, both researchers affiliated with leading Boston-area academic institutions. It has built a Scientific Advisory Board including Dougan, Hafler, and Hodges, and has added Jim Weissman to its Board of Directors. Reported headcount is 1-10 employees, consistent with its preclinical status and capital base.

Cerberus Therapeutics is currently pre-revenue and pre-commercial, with no clinical-stage assets. It has raised approximately $9 million in disclosed funding across two rounds: a $4 million seed round from Sherpa Healthcare Partners in December 2021, and a $5 million investment from the Bill & Melinda Gates Foundation in December 2023. The company has additionally received Golden Ticket awards from Novo Nordisk (2023), Biogen (2022), and AbbVie-LabCentral (2022), which typically confer lab space, reagents, and access to pharma expertise. As a preclinical company with no approved products, revenue mechanics are not yet established.

Short descriptiontext

Cerberus Therapeutics is a preclinical, Cambridge, MA-based biotech developing proprietary VHH (nanobody) platforms targeting autoimmune disease (Tolerance Induction) and infectious disease (KappaLink). Founded in 2021, it is pre-revenue with approximately $9 million in disclosed funding.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanobody therapeutics, autoimmune disease treatment, infectious disease therapeutics, VHH antibody platforms, immunomodulation biotechnology
Industry2 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Licensing and Development Partnerships
TypeLicensing Royalties
Description

Pre-commercial biotech company generating revenue through strategic partnerships with pharmaceutical companies for development and commercialization of nanobody-based therapeutics. Programs in autoimmunity and infectious diseases are in preclinical development.

cerberustx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Tolerance Induction Platform
Description

A nanobody-based platform that targets MHCII to engage all types of professional antigen presenting cells for immune tolerance induction in autoimmune diseases.

cerberustx.com
+1 more record
Core offering1 text field

Cerberus Therapeutics is a preclinical-stage biotechnology company developing proprietary nanobody-based (VHH) immunotherapeutic platforms. Its Tolerance Induction Platform targets MHCII to rewire the immune system toward tolerance in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis. Its KappaLink Platform creates VHH-based adducts that engage polyclonal antibodies and activate complement to provide protective immunity against infectious diseases including influenza, SARS-CoV-2, and HIV.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Single dose administration for minimal toxicity in autoimmune applications
+3 more records
Product overview1 text field

Cerberus Therapeutics is a platform company developing two distinct nanobody-based immunotherapeutic platforms built on alpaca-derived VHH (variable domain of heavy chain-only antibody) technology. The Tolerance Induction Platform targets autoimmune diseases by engaging antigen presenting cells via MHCII to rewire the immune system toward tolerance. The KappaLink Platform addresses infectious diseases by using engineered VHHs that recognize antibody light chains, creating adducts that activate complement and mount protective immune responses. Both platforms exploit the unique biochemical properties of nanobodies—small molecular weight (~1/10 of traditional antibodies), high affinity, rapid tissue penetration, and low immunogenicity—to enable single-dose administration with potential curative outcomes.

Product and service3 records
1Tolerance Induction Platform
CategoryAutoimmune immunotherapy platform
Description

A proprietary nanobody-based immunotherapeutic platform that targets MHCII antigens on professional antigen-presenting cells (dendritic cells, macrophages, B cells) to induce antigen-specific immune tolerance for the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis.

2KappaLink Platform
CategoryInfectious disease immunotherapy platform
Description

A proprietary infectious disease platform using engineered VHHs that recognize antibody light chains (immunoglobulin kappa chain), combined with small-molecule antivirals or pathogen-specific VHHs to create adducts that activate complement and engage polyclonal antibodies (IgG, IgM, IgA, IgE) for protective immunity against influenza, SARS-CoV-2, and HIV.

3VHH (Nanobody) Technology
CategoryCore biotechnology platform
Description

Core proprietary alpaca-derived single-domain antibody fragment (VHH) technology with molecular weight approximately one-tenth that of traditional antibodies, high antigen-binding affinity, high solubility and stability, rapid tissue penetration, fast clearance, low immunogenicity, and cost-efficient manufacturing in microbial systems.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

argenx is the leading commercial-stage nanobody (VHH) biotech with efgartigimod approved in autoimmune disease (myasthenia gravis, ITP). It is the most direct comparable to Cerberus's Tolerance Induction Platform because both companies commercialize VHH-derived therapeutics for autoimmune indications.

TypeDirect peer
Description

AbCellera operates a technology platform for antibody discovery including single-domain/nanobody workflows with pharma partnerships. Comparable to Cerberus as a platform company monetizing VHH-enabled drug discovery through partnerships.

3Selecta Biosciences
TypeDirect peer
Description

Selecta developed antigen-specific immune tolerance therapies (ImmTOR platform) for autoimmune disease and gene therapy immunomodulation. Directly comparable to Cerberus's Tolerance Induction Platform, which similarly aims to rewire immune responses against specific antigens.

TypeEmerging player
Description

Anokion is a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases (celiac, MS). Comparable to Cerberus's autoimmune tolerance approach via a different molecular strategy (protein-engineered antigens vs. VHH-MHCII targeting).

TypeEmerging player
Description

Eligo Bioscience is a preclinical/early-clinical biotech using engineered payloads (including nanobody-based phage-derived particles) to modulate the microbiome and immune system. Overlaps with Cerberus's nanobody-based immune modulation approach in an emerging modality niche.

TypeEmerging player
Description

Crescendo Biologics develops T cell engagers built on a humanized VHH (Humabody) domain platform for cancer and autoimmune disease. Comparable to Cerberus because both commercialize VHH domain-based therapeutics targeting immune cells.

TypeEmerging player
Description

Compass Therapeutics is a clinical-stage immuno-oncology and autoimmune biotech with antibody platforms including bispecifics. Comparable to Cerberus as a small-cap immunology platform company with partnership-driven business model.

TypeEmerging player
Description

Adagene is a clinical-stage biotech using antibody engineering and masking technologies (POWERbody and SAFEbody platforms) to develop targeted immuno-oncology therapeutics. Comparable as a small-cap antibody-engineering platform company pursuing partnered clinical development.

TypeEmerging player
Description

Merus is a clinical-stage oncology biotech developing bispecific antibody therapeutics (Biclonics and Triclonics platforms). Comparable to Cerberus as a smaller-cap engineered antibody platform company with partnership-licensed assets.

TypeBroad incumbent
Description

Sanofi acquired Ablynx in 2018 for its nanobody platform (now marketed as ozanimod-class franchises and internal VHH programs). Comparable to Cerberus as the broad incumbent that established nanobodies as a commercial modality, defining both the opportunity and competitive ceiling for VHH biotechs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerberus Therapeutics

Biopharmaceuticalscerberustx.com

Cerberus Therapeutics is a preclinical, Cambridge, MA-based biotech developing proprietary VHH (nanobody) platforms targeting autoimmune disease (Tolerance Induction) and infectious disease (KappaLink). Founded in 2021, it is pre-revenue with approximately $9 million in disclosed funding.

What Cerberus Therapeutics does

Cerberus Therapeutics is a preclinical biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops VHH (variable heavy domain of heavy-chain-only antibody), or nanobody, platforms organized around two distinct programs: a Tolerance Induction platform for autoimmune diseases and a KappaLink platform for infectious diseases. Its technology is based on single-domain antibodies derived from camelid heavy-chain-only antibodies and is positioned for therapeutic applications in immunology and infectious disease indications.

The company was co-founded by Novalia Pishesha, who serves as CEO, alongside scientific co-founders Hidde Ploegh and Harvey Lodish, both researchers affiliated with leading Boston-area academic institutions. It has built a Scientific Advisory Board including Dougan, Hafler, and Hodges, and has added Jim Weissman to its Board of Directors. Reported headcount is 1-10 employees, consistent with its preclinical status and capital base.

Cerberus Therapeutics is currently pre-revenue and pre-commercial, with no clinical-stage assets. It has raised approximately $9 million in disclosed funding across two rounds: a $4 million seed round from Sherpa Healthcare Partners in December 2021, and a $5 million investment from the Bill & Melinda Gates Foundation in December 2023. The company has additionally received Golden Ticket awards from Novo Nordisk (2023), Biogen (2022), and AbbVie-LabCentral (2022), which typically confer lab space, reagents, and access to pharma expertise. As a preclinical company with no approved products, revenue mechanics are not yet established.

Cerberus Therapeutics firmographics

Firmographics
Name
Cerberus Therapeutics
Legal name
Cerberus Therapeutics, Inc.
Website
https://cerberustx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Cerberus Therapeutics is a preclinical, Cambridge, MA-based biotech developing proprietary VHH (nanobody) platforms targeting autoimmune disease (Tolerance Induction) and infectious disease (KappaLink). Founded in 2021, it is pre-revenue with approximately $9 million in disclosed funding.
Ownership category
akta.pro rank

Cerberus Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Nanobody therapeutics
  • Autoimmune disease treatment
  • Infectious disease therapeutics
  • VHH antibody platforms
  • Immunomodulation biotechnology

Where Cerberus Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cerberus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Licensing and Development Partnerships: Pre-commercial biotech company generating revenue through strategic partnerships with pharmaceutical companies for development and commercialization of nanobody-based therapeutics. Programs in autoimmunity and infectious diseases are in preclinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Cerberus Therapeutics product offering

Product offering

Core offering

Cerberus Therapeutics is a preclinical-stage biotechnology company developing proprietary nanobody-based (VHH) immunotherapeutic platforms. Its Tolerance Induction Platform targets MHCII to rewire the immune system toward tolerance in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis. Its KappaLink Platform creates VHH-based adducts that engage polyclonal antibodies and activate complement to provide protective immunity against infectious diseases including influenza, SARS-CoV-2, and HIV.

Product overview

Cerberus Therapeutics is a platform company developing two distinct nanobody-based immunotherapeutic platforms built on alpaca-derived VHH (variable domain of heavy chain-only antibody) technology. The Tolerance Induction Platform targets autoimmune diseases by engaging antigen presenting cells via MHCII to rewire the immune system toward tolerance. The KappaLink Platform addresses infectious diseases by using engineered VHHs that recognize antibody light chains, creating adducts that activate complement and mount protective immune responses. Both platforms exploit the unique biochemical properties of nanobodies—small molecular weight (~1/10 of traditional antibodies), high affinity, rapid tissue penetration, and low immunogenicity—to enable single-dose administration with potential curative outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • Tolerance Induction Platform: A nanobody-based platform that targets MHCII to engage all types of professional antigen presenting cells for immune tolerance induction in autoimmune diseases.
  • KappaLink Platform

Products and services

  • Tolerance Induction Platform A proprietary nanobody-based immunotherapeutic platform that targets MHCII antigens on professional antigen-presenting cells (dendritic cells, macrophages, B cells) to induce antigen-specific immune tolerance for the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis.
  • KappaLink Platform A proprietary infectious disease platform using engineered VHHs that recognize antibody light chains (immunoglobulin kappa chain), combined with small-molecule antivirals or pathogen-specific VHHs to create adducts that activate complement and engage polyclonal antibodies (IgG, IgM, IgA, IgE) for protective immunity against influenza, SARS-CoV-2, and HIV.
  • VHH (Nanobody) Technology Core proprietary alpaca-derived single-domain antibody fragment (VHH) technology with molecular weight approximately one-tenth that of traditional antibodies, high antigen-binding affinity, high solubility and stability, rapid tissue penetration, fast clearance, low immunogenicity, and cost-efficient manufacturing in microbial systems.

Quantifiable outcome

  • Single dose administration for minimal toxicity in autoimmune applications
  • +3 more outcomes

Companies that use Cerberus Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Cerberus Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cerberus Therapeutics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Cerberus Therapeutics competitors and assessment

Company assessment

Direct peers

  • argenx: argenx is the leading commercial-stage nanobody (VHH) biotech with efgartigimod approved in autoimmune disease (myasthenia gravis, ITP). It is the most direct comparable to Cerberus's Tolerance Induction Platform because both companies commercialize VHH-derived therapeutics for autoimmune indications.
  • AbCellera Biologics: AbCellera operates a technology platform for antibody discovery including single-domain/nanobody workflows with pharma partnerships. Comparable to Cerberus as a platform company monetizing VHH-enabled drug discovery through partnerships.
  • Selecta Biosciences: Selecta developed antigen-specific immune tolerance therapies (ImmTOR platform) for autoimmune disease and gene therapy immunomodulation. Directly comparable to Cerberus's Tolerance Induction Platform, which similarly aims to rewire immune responses against specific antigens.

Emerging players

  • Anokion: Anokion is a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases (celiac, MS). Comparable to Cerberus's autoimmune tolerance approach via a different molecular strategy (protein-engineered antigens vs. VHH-MHCII targeting).
  • Eligo Bioscience: Eligo Bioscience is a preclinical/early-clinical biotech using engineered payloads (including nanobody-based phage-derived particles) to modulate the microbiome and immune system. Overlaps with Cerberus's nanobody-based immune modulation approach in an emerging modality niche.
  • Crescendo Biologics: Crescendo Biologics develops T cell engagers built on a humanized VHH (Humabody) domain platform for cancer and autoimmune disease. Comparable to Cerberus because both commercialize VHH domain-based therapeutics targeting immune cells.
  • Compass Therapeutics: Compass Therapeutics is a clinical-stage immuno-oncology and autoimmune biotech with antibody platforms including bispecifics. Comparable to Cerberus as a small-cap immunology platform company with partnership-driven business model.
  • Adagene: Adagene is a clinical-stage biotech using antibody engineering and masking technologies (POWERbody and SAFEbody platforms) to develop targeted immuno-oncology therapeutics. Comparable as a small-cap antibody-engineering platform company pursuing partnered clinical development.
  • Merus: Merus is a clinical-stage oncology biotech developing bispecific antibody therapeutics (Biclonics and Triclonics platforms). Comparable to Cerberus as a smaller-cap engineered antibody platform company with partnership-licensed assets.

Broad incumbents

  • Sanofi (Ablynx): Sanofi acquired Ablynx in 2018 for its nanobody platform (now marketed as ozanimod-class franchises and internal VHH programs). Comparable to Cerberus as the broad incumbent that established nanobodies as a commercial modality, defining both the opportunity and competitive ceiling for VHH biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Cerberus Therapeutics social profiles

Digital presence

Cerberus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerberus Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Cerberus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerberus Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerberus Therapeutics

What does Cerberus Therapeutics do?

Cerberus Therapeutics is a preclinical-stage biotechnology company developing proprietary nanobody-based (VHH) immunotherapeutic platforms. Its Tolerance Induction Platform targets MHCII to rewire the immune system toward tolerance in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis. Its KappaLink Platform creates VHH-based adducts that engage polyclonal antibodies and activate complement to provide protective immunity against infectious diseases including influenza, SARS-CoV-2, and HIV.

Is Cerberus Therapeutics a public or private company?

Cerberus Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cerberus Therapeutics founded?

Cerberus Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is Cerberus Therapeutics based?

Cerberus Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Cerberus Therapeutics make money?

One revenue line is on record: pharmaceutical Licensing and Development Partnerships.

Who are Cerberus Therapeutics's main competitors?

Direct peers on record are argenx, AbCellera Biologics and Selecta Biosciences. Emerging players are Anokion, Eligo Bioscience, Crescendo Biologics, Compass Therapeutics, Adagene and Merus. Sanofi (Ablynx) is listed as a broad incumbent.

Does Cerberus Therapeutics have an API?

No public API is recorded for Cerberus Therapeutics.

What industry is Cerberus Therapeutics in?

Cerberus Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales